correlated with the age of HD onset, making it possible to predict the approximate disease onset (Rosenblatt et al., 2012) . A variable with the form of age times CAG repeat-the approximate threshold for disease-termed the CAG Age Product or "CAP" score has been found to be a useful way of tracking the extent of exposure to the CAG repeat expansion mutation. Motor onset of manifest HD is defined when a clinician determines that there is an extrapyramidal movement disorder indicative of HD in someone at risk. Individual mutation status can be identified by genetic testing years before clinical symptoms appear (Chan et al., 2014) . There is no diseasemodifying treatment currently available, though strategies for Htt protein lowering via RNA interference are being developed, using antisense oligonucleotides to be delivered intrathecally, or AAV vectors to be delivered intra-parenchymally (Wild & Tabrizi, 2017) .
Sensitive and robust imaging biomarkers are therefore desired to monitor disease progression, and to help develop novel therapeutic approaches and new drugs for disease intervention, especially at the premanifest stage.
Brain atrophy measured through structural MRI especially in the striatum is an imaging biomarker for HD that can be detected before the onset of disease symptoms (Aylward et al., 2004; Ross et al., 2014) , which has been demonstrated in large-scale longitudinal studies (Aylward et al., 2012; Tabrizi et al., 2012 Tabrizi et al., , 2013 van den Bogaard et al., 2011) . Besides brain atrophy, abnormal iron accumulation in the brain is commonly recognized as an important marker of pathological neuronal damage (Dixon & Stockwell, 2014) , and may predispose individuals to high risk of motor and cognitive function decline . Increased iron accumulation in the basal ganglia and cortical regions has been associated with neurodegenerative diseases such as Parkinson's disease (Du et al., 2016; He et al., 2015) and Alzheimer's disease (Ayton et al., 2017; van Bergen, Li et al. 2016; Zecca, Youdim, Riederer, Connor, & Crichton, 2004) . Abnormal iron deposition has long been suggested to play a role in HD pathophysiology (Bartzokis et al., 2007; Rosas et al., 2012) . Since normal Htt protein is required for iron homoeostasis (Hilditch-Maguire et al., 2000) , mutant HTT may lead to abnormally increased tissue iron through different mechanisms in iron metabolism (Gomez-Tortosa et al., 2001; Rivera-Mancia et al., 2010) . Different MR imaging techniques have been used to measure brain iron levels in HD. For example, increased iron levels in the basal ganglia have been indicated in manifest HD by using transverse relaxation time (T 2 ) or T 2 -weight hypointensity (Jurgens et al., 2010; Vymazal et al., 2007) . increase imaging and suggested that the ferritin levels in the striatum were significantly increased in HD (Bartzokis et al., 2007) . Other MRI iron imaging techniques such as magnetic field correlation (Dumas et al., 2012) , effective relaxation rate (R * 2 ) (Sanchez-Castaneda et al., 2015) , and phase imaging (Rosas et al., 2012) have also been used to study brain iron levels in HD. However, known technical limitations of these imaging methods could lead to reduced sensitivity and specificity to disease-related tissue iron changes (Haacke et al., 2005; Ropele & Langkammer, 2017; Wang & Liu, 2015 (Deistung et al., 2013; Langkammer et al., 2012; Lim et al., 2013) , with high sensitivity and specificity to tissue iron changes (Chen et al., 2017; Deistung, Schweser, & Reichenbach, 2017; Langkammer et al., 2018; Liu, Li, Tong, Yeom, & Kuzminski, 2015; Wang et al., 2017) .
Using quantitative susceptibility as an imaging measure of tissue iron, recent studies have shown elevated iron levels in the striatum and globus pallidus in premanifest HD patients as compared to matched controls (Dominguez et al., 2016; van Bergen, Hua et al., 2016a) . Such changes in iron levels have also been found to correlate with striatal atrophy and CAP score (Dominguez et al., 2016; van Bergen, Hua et al., 2016a) . However, the natural history of abnormal iron deposition in HD is still not well understood. When extra iron starts to deposit in the striatum during the long premanifest stage, how the iron deposition rate changes as the disease progresses has not been reported.
This study therefore aims to investigate altered brain iron content (as measured indirectly through magnetic susceptibility ) in premanifest HD at different time lengths to onset and early stage HD, and to assess the iron deposition rate in these patients through a longitudinal one-year follow-up test. In the present study, QSM and R * 2 measures were quantified in select brain regions that have been reported to be affected in HD including the striatum and globus pallidus. Other brain regions including the hippocampus, substantia nigra, and red nucleus that are related to movement and cognition functions (Middleton & Strick, 2000; Williams, Kim, & Martin, 2014) were also included. HD patients were divided into three disease stages: (i) more than 8 years before estimated onset (further-from-onset), (ii) less than 8 years before estimated onset (closer-to-onset), and (iii) early stage HD, and compared with healthy controls. Potential associations between iron level,
Significance
This study tried to investigate the natural history of altered brain iron content at different stages of premanifest and manifest Huntington's disease (HD). Two significant findings are shown. First, higher magnetic susceptibility values as measured by QSM indicating higher iron content in the striatum and globus pallidus were observed in closer-to-onset premanifest HD and early HD patients, but not in the further-from-onset premanifest HD group as compared to the controls. Second, significantly higher iron deposition rates (11.9%/years in caudate and 6.1%/years in globus pallidus)
were observed in closer-to-onset premanifest HD and early HD as compared to the controls over a one-year time period.
structure volume, and clinical assessment were tested. For the longitudinal study, closer-to-onset and early stage HD patients were pooled due to limited sample size. Differences in the changing rate of iron deposition, atrophy, and clinical measures in HD patients were tested in comparison with controls using the General Linear Model (GLM).
| MATERIAL S AND ME THODS

| Subjects
Twenty-four subjects (13 males and 11 females) carrying CAG-expanded HTT allele were recruited through the Baltimore Huntington Disease center at the Johns Hopkins University School of Medicine.
The age range of these patients was from 24 to 60 years old (mean ± SD of 44.8 ± 15.8 y/o). In addition, 16 age-matched healthy controls (8 males, 8 females; 42.5 ± 12.9 y/o) were also recruited.
For the longitudinal study, 14 out of the 24 CAG-expanded HTT allele carriers and 7 out of the 16 controls participated in a follow-up exam after approximately one year (1.0 ± 0.1 years). All the aspects of the study were approved by the Johns Hopkins University
Institutional Review Board, and all the participants gave written informed consent.
To estimate the progression status of HD pathology in the patients, the CAG-age product scaled (CAPs) score as CAPs = Age × (CAG-33.66)/432.3326 was calculated based on age at study entry and CAG repeat length (Zhang et al., 2011) . According to the CAPs score and predicted disease onset age, all the carriers (N = 24) were further divided into three groups, ">8 years pre-HD" (N = 9) for premanifest HD patients with estimated disease onset beyond 8 years (further-from-onset), "<8 years pre-HD" (N = 6) for premanifest HD patients with estimated onset within 8 years (closer-to-onset), and "early HD" (N = 9) for participants with early stage HD. The numbers of carriers in the >8 years pre-HD, <8 years pre-HD, and early HD groups who participated in the one-year follow-up were 6, 4, 4, respectively. 
| MRI Measures
Subjects were imaged on a 7 T Achieva scanner (Philips Healthcare, UHDRS function score 24.9 ± 0.5 23.3 ± 3.5 * 25.0 ± 0.0 23.0 ± 4.0 21.7 ± 4.4 * UHDRS behavior score 3.5 ± 4.7 9.6 ± 11.2 * 7.0 ± 5.7 7.7 ± 4.5 13.6 ± 16.9
Total functional capacity 13 ± 0.0 11.5 ± 3.0 * 12.9 ± 0.3 11.0 ± 3.3 10.3 ± 3.9
Montreal cognitive assessment 29. =1530 Hz/voxel, SENSE factor of 2.5 × 2, transverse slab, scan time = 7 min 14 s. Both magnitude and phase images were saved for QSM reconstruction. In addition, a 3D T1-weighted MPRAGE sequence was used for anatomical referencing, automated image segmentation, and for measuring brain structure volume with the following parameters: TR/TE = 4.1/1.8 ms, voxel size =1 × 1 × 1 mm 3 , sagittal acquisition with FOV = 220 × 220 × 180 mm 3 , TFE factor of 352, SENSE factor of 2 × 2, scan time = 2 min 20 s. All images were examined for possible image artifacts or abnormalities.
| Quantitative Susceptibility and R 2 * Mapping
Several processing steps were applied to reconstruct the quantitative susceptibility maps from the GRE phase images. First, phase wraps in the GRE phase images were removed by a Laplacian-based phase unwrapping method (Li, Wu, & Liu, 2011) . The GRE magnitude image at the first echo (TE = 4 ms) was skull-stripped using FSL BET (Smith, 2002) and eroded 2 voxels to obtain a brain mask. Frequency shift maps (in Hz) were then obtained by dividing the phase by 2π*TE.
Subsequently, the background field was removed by using the VSHARP method with a maximum kernel radius of 6 mm and a truncated svd regularization threshold of 0.05 (Schweser, Deistung, Lehr, & Reichenbach, 2011; Wu, Li, Guidon, & Liu, 2012) . After removal of the background field, the resulting local frequency shift maps of the last five echoes (with TEs of 10-18 ms) were averaged to obtain a higher signal-to-noise ratio (SNR) as compared to single-echo reconstruction (Wu, Li, Avram, Gho, & Liu, 2012) . The ill-conditioned QSM dipole inversion was solved by using a modified structural feature-based collaborative reconstruction algorithm (SFCR) (Bao, Li, Cai, Chen, & Zijl, 2016) with only L1-norm-based regularization i.e., 1 = 1 = 100 and 2 = 2 = 0 and an updated adaptive ADMM solver (Chan, Khoshabeh, Gibson, Gill, & Nguyen, 2011) . The final reported susceptibility values for each subject were referenced to the mean susceptibility values of the CSF regions in the frontal and body parts of the lateral ventricles.
In addition, R * 2 maps were reconstructed by mono-exponential fitting to the square of the magnitude data of all available echoes in each voxel using the power method (Deistung et al., 2013) .
| Image Segmentation Protocol
The procedures for segmenting the regions of interest (ROIs) in deep gray matter were as follows. First, the T 1 -weighted MPRAGE image was co-registered to the GRE magnitude image acquired at TE of 8 ms. The co-registered T 1 image was then segmented using a multi-atlas matching approach which is developed as part of the Johns Hopkins University brain atlas (Tang et al., 2015; Zhang et al., 2014) . The selected ROI masks in the caudate nucleus, putamen, globus pallidus, hippocampus, substantia nigra, and red nucleus were extracted. In addition, masks of the CSF regions in the lateral ventricle were also extracted to be used as QSM reference regions. Manual corrections on the main ROI masks were performed based on magnetic susceptibility contrast, while the CSF masks were corrected based on T 1 contrast if deemed necessary after visual checking (by L.C. 
| Statistical analysis
To investigate the differences in the brain iron content and structure volume between the CAG-expanded HTT allele carriers and the con- [n = 14]) as a between subject factor, and age and gender were set as potential confounders. The GLM model can be specified as x1 = time + time × group + time × age + time × gender + error term.
When a significant group ×time interaction effect was found, post hoc analyses were performed within groups using a separate GLM with time as a repeated measures factor which can be written as x2 = time + time × age + time × gender + error term. Since it has been demonstrated that atrophy rate in the striatum and the decline rate of various clinical and cognitive measures increase steadily during the progression of the Huntington disease and may even accelerate when closer to or after disease onset (Ross et al., 2014; Tabrizi et al., 2013) , it is also reasonable to assume that HD patients at different disease stages may have different iron deposition rates. Thus, a similar GLM analysis was conducted with <8 years pre-HD and early HD patients pooled together as a group (n = 8) to be tested against the control group. Subsequently, changes in clinical and MRI-based measurements over time were analyzed by using GLMs for repeated measures with time (2 levels) as a repeated measures factor, group (control [n = 7] vs. HD-2 group (defined as <8 years pre-HD group plus early HD group) [n = 8]) as a between subject factor, and age and gender added as covariates. When a significant group ×time interaction effect was found, post hoc analyses were performed within groups using a separate GLM with time as a repeated measures factor.
| RE SULTS
As a whole group, all HD patients displayed no differences as compared to the controls in terms of gender, age, education, and Verbal Fluency Test score, but showed higher UHDRS behavior score and lower UHDRS function score, total functional capacity, and Montreal cognitive assessment than the controls (p < 0.05). In the longitudinal study, no significant group ×time interaction effects in clinical measurement, magnetic susceptibility, R * 2 , and corrected volume were found between the controls and the whole HD group from the baseline to the one-year follow-up by means of the GLMs (Table 3) iron content in the striatum and globus pallidus were observed in closer-to-onset premanifest HD and early HD patients, but not in the further-from-onset premanifest HD group (>8 years, an average of 20 years in this study) as compared to the controls.
| D ISCUSS I ON
Though limited by the small sample size, this study to the best of our knowledge is the first to investigate altered brain iron content in premanifest HD at different time lengths to onset. Second, significantly higher iron deposition rates (11.9%/years in the caudate and 6.1%/years in the globus pallidus) were observed in closer-to-onset premanifest HD and early HD as compared to the controls from our longitudinal study over the one-year time period. Such findings, not reported before, help us gain more knowledge and insight on the natural history of abnormal iron deposition in HD, i.e., when extra iron starts to deposit in the striatum during the long premanifest stage, and how the iron deposition rate changes as the disease progresses.
With regard to elevated iron deposition in the caudate and putamen in premanifest HD as measured indirectly using QSM, F I G U R E 2 Mean magnetic susceptibility (a), R * 2 (b), and corrected volume (c) in each ROI of the control, >8 years pre-HD, <8 years pre-HD, and early HD groups. The boxes shaded with lighter colors denote the 95% CI and the darker colors denote ± 1 SD. The red lines represent the mean. *, **, and *** indicate significant differences with p < 0.05, p < 0.01 and p < 0.001 controlling for age and gender. Correlation analysis of magnetic susceptibility (d) and R * 2 (e) with corrected structure volumes while controlling for age and gender in all HD patients. CN: caudate nucleus, PT: putamen, GP: globus pallidus, HIPP: hippocampus, SN: substantia nigra, RN: red nucleus [Color figure can be viewed at wileyonlinelibrary.com] the present study agrees in general with the previous studies performed by us and others (Dominguez et al., 2016; van Bergen et al., 2016a) . It was noticed that the premanifest HD populations in the previous studies resemble the <8 years premanifest (closer-toonset) HD group more in this study in terms of disease stage, i.e., with a mean CAPs score of 0.9 (van Bergen, Hua et al., 2016a) or 0.85 (Dominguez et al., 2016) . Such elevated iron deposition rate was observed to be not significant in the further-from-onset stage, i.e., in the >8 years premanifest HD group in this study (20.3 ± 10.9 estimated years to onset). Such nonsignificance in brain iron changes at a very early stage of the disease could of course be due to the small sample size used in this study. Such elevated iron deposition becomes more obvious at the closer-to-onset stage (3.8 ± 2.5 estimated years to onset). Elevated iron content in the globus pallidus was only found to be significant in the early HD patients in the present study (using either QSM or R * 2
). This is discrepant with the two previous QSM studies showing elevated tissue susceptibility in the globus pallidus in premanifest HD. Such discrepancy is attributed partly to the limited sample size in the <8 years pre-HD group (n = 6) in the present study.
In terms of brain atrophy, our study results are consistent with the existing literature suggesting HD-related neuronal damage is to begin from the striatum (more significant volume loss), whereas a secondary neurodegenerative process may affect the globus pallidus and substantia nigra (Ross & Tabrizi, 2011; van Bergen, Hua et al., 2016a) . Controversies still exist considering the atrophy in the globus pallidus in the premanifest stages. Our previous study reported no significant decrease in the volume of globus pallidus in the premanifest HD with observed susceptibility changes (van Bergen, Hua et al., 2016a), while several other studies reported the opposite (Jurgens et al., 2008; van den Bogaard et al. 2011 ). The present study further suggests that the volume loss in globus pallidus is distinguishable in the <8 years pre-HD group, but not in the >8 years pre-HD group agreeing with the general understanding that brain atrophy becomes more severe as the disease progresses. In addition, the atrophy in the caudate and putamen, which happens in a decade or more before predicted disease onset (Aylward et al., 1996;  van den Bogaard et al. 2011), was not found in the >8 years pre-HD group in our study. This is most likely due to the small sample size and relatively long time to disease onset of this group of patients (20 years to onset on average), thus leading to a relatively small effect size of atrophy. Furthermore, the corrected volume in some regions, e.g., in the putamen of the HD and HD-2 groups, over oneyear time showed some increase (Table 3) , though not statistically significant. The reason for such increase may be partly due to the inaccuracy of the anatomical parcellation, i.e., in the ROI delineation procedure. Note that since we defined these ROIs mainly based on susceptibility contrast, it may be possible that the boundaries of these deep gray matter regions expand visually on QSM maps due to extra iron deposition or demyelination in the surrounding white matter area.
The significant correlations between corrected ROI volumes and iron levels in the caudate, putamen, and globus pallidus demonstrate that atrophy and iron deposition in the striatum and pallidum observed in HD are two processes that are linked in time, which agrees with previous studies using R * 2 and QSM (Dominguez et al., 2016; van Bergen, Hua et al., 2016a) . It should be noted that our current study cannot rule out the possibility that the observed increase in tissue iron level in the striatum simply reflects the effect of atrophy assuming iron remains in place while structural loss happens, i.e., iron concentration increases without increase in total iron content. However, this is less likely the case when considering previous studies showing unmatched tissue iron changes and atrophy (Dumas et al., 2012; van Bergen, Hua et al., 2016a) in addition to the suggested involvement of Htt in the regulation of brain iron homeostasis (Dietrich, Johnson, Alli, & Dragatsis, 2017; Muller & Leavitt, 2014) .
It is widely known that CAG repeats play an important role in HD disease toxicity, and CAG repeat length and age at study entry (i.e., progression and faster striatal atrophy .
Our results provide further support to this showing that higher CAPs score is indeed associated with greater atrophy in the caudate, putamen, and globus pallidus. In addition, our results further confirm that the elevated brain iron in the striatum is associated with CAPs or disease severity found in previous studies (Dominguez et al., 2016; van Bergen, Hua et al., 2016a) . It still remains unclear whether iron deposition in the basal ganglia is a primary cause of tissue damage, or is a secondary effect of other neuronal damages. However, considering its correlation with CAPs, iron content may serve as a potential alternative marker for monitoring therapy for disease intervention that would lead to detectable brain iron changes.
The increased iron contents in the basal ganglia in the premanifest and manifest HD groups are further confirmed by the increased R * 2 values in the caudate and putamen, consistent with our previous study (van Bergen, Hua et al., 2016a) . Another R * 2 study however only showed higher R * 2 in pre-symptomatic HD in left caudate (Sanchez-Castaneda et al., 2015) . The absence of a R * 2 TA B L E 3 Clinical assessment scores and MRI measurements in select ROIs of the controls, HD group, and HD-2 group over one-year time and the corrected ROI volume in the putamen suggest a lower detection sensitivity and accuracy of R * 2 maps to tissue iron levels in comparison with QSM, which was also concluded in previous studies (Chen et al., 2017; Dominguez et al., 2016; van Bergen, Hua et al., 2016a) . This is partly because R * 2 contrast can be easily contaminated by field inhomogeneity effects unrelated to tissue iron content (Barbosa et al., 2015; Wang & Liu, 2015) .
Due to the small sample size of patients who completed the one-year follow-up, we tried to pool them together into a whole HD group for our first longitudinal analysis. Group differences in longitudinal changes for this HD group were however not statistically significant for magnetic susceptibility, R * 2 values, structure volume as well as cognitive function measurements as compared to the controls. However, subsequent analysis showing significantly higher one-year iron deposition rates in the caudate and globus pallidus, and higher volume loss rate in the caudate in the HD-2 group (combined closer-to-onset and early HD) compared to the controls and no significant difference in the whole HD group compared to the controls is consistent with the reported steadily increased atrophy rate in the striatum during the progression of the HD from further-from-onset to closer-to-onset and afterward (Ross et al., 2014; Tabrizi et al., 2013) . The nonsignificant structural volume loss in the whole HD-group and the significant atrophy found only in the caudate in the HD-2 group are somewhat diverse to the previous literature reporting early atrophy in HD and are likely caused by the rather small sample size. Nevertheless, this study suggests for the first time that the iron deposition rate in the striatum may follow a similar pattern of acceleration of striatal atrophy in HD, i.e., faster iron deposition rate at closer-to-onset and early HD than further-from-onset stage.
The present results are consistent with the gain-of function model for HD pathogenesis, i.e., loss of Htt expression in adulthood has been reported to cause decreased rather than increased iron (Dietrich et al., 2017) . One consequence of the increased delineation of the basal ganglia structures, especially the striatum using QSM, might be to facilitate the mapping of these structures in patients for neurosurgical interventions (Wild & Tabrizi, 2017 ).
The present study does have limitations. Other potential sources such as calcium and other trace metal elements may influence the iron assessment by magnetic susceptibility. However, such effects should be limited (Drayer et al., 1986 ) and the increase of magnetic susceptibility observed in our study should reflect primarily increased tissue iron content, consistent with other QSM studies (Ayton et al., 2017; Bilgic, Pfefferbaum, Rohlfing, Sullivan, & Adalsteinsson, 2012; Du et al., 2016; Ropele & Langkammer, 2017; Schweser et al., 2011; Shmueli et al., 2009) . The second limitation is the small sample size and relatively short follow-up period (one year) employed in this study. The sample size is especially limited for the closer-to-onset and early HD patients who completed the follow-up (n = 4 in each subgroup), which made it impossible to test them as a separate group in the longitudinal analysis. Further studies with larger sample size and longer follow-up periods are needed to further validate the present findings.
| CON CLUS IONS
The present study confirms that increased iron deposition in the striatum can be measured by QSM in premanifest and manifest Huntington's disease and thus has the potential to serve as a marker to monitor disease progression. The altered iron content in the striatum is indicated to be more obvious in the closer-to-onset stage and less so in the further-from-onset stage. The inverse correlations between the structural volumes and iron levels in the striatum and globus pallidus indicate volume loss and iron accumulation are two time-locked processes. Both iron deposition and volume loss are related to disease progression as indicated by their correlations with CAPs score. Furthermore, we have shown through a one-year longitudinal study that iron deposition rate in the caudate and globus pallidus is also higher in the closer-to-onset and early stage HD patients than the controls. 
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